AD/PD™ Journal Club – Circulating Biomarkers and the ATN Classification: Challenges and Opportunities in Low-Resource Settings

Mark your calendars for the next AD/PD™ Journal Club!

Dr. Luc Belinga will present insights from the latest publication, “Circulating Biomarkers for Alzheimer’s Disease: Unlocking the Diagnostic Potential in Low-and Middle-Income Countries, focusing on Africa”.

Date: 30 April 2025 Time: 16:00 CEST

Don’t miss this opportunity to gain valuable insights and participate in the discussion!

The author’s paper is available for free to all journal attendees.

READ ARTICLE

Agenda:

16:00- 16:10 – Welcome and Introductions by Dr. Giulia Bommarito

16:10-16:30 – Presentation of the article: “Circulating Biomarkers for Alzheimer’s Disease: Unlocking the Diagnostic Potential in Low-and Middle-Income Countries, Focusing on Africa” by Dr. Nwamekang Belinga

16:30 – 16:45 – Q&A session led by Dr. Giulia Bommarito

This initiative is made possible thanks to the help of the Neorodegenerative Diseases Journal, Karger Publishers.

Faculty

Moderator

Giulia Bommarito
CHUV-UNIL

Neurologist, Dr. Giulia Bommarito completed her clinical education at the University of Padua and University of Genoa, Italy. She developed her research skills in neuroimaging, neuroinflammatory and neurodegenerative disorders at the Mount Sinai School of Medicine, New York, EPFL-University of Geneva, Geneva. She’s currently employed as chief resident at the Leenaards Memory Center, CHUV, Lausanne.

Speaker

Luc Belinga
Leenaards Memory Center, Center of Psychiatric Neurosciences, Vaudois University Hospital

I am a medical doctor with a background in emergency medicine and neurosurgery internships, driven by a passion for translational Neurosciences research. My work focuses on making diagnostic tools more accessible for neuropsychiatric disorders, especially in diverse biological and environmental contexts. As a Swiss government scholarship recipient and PhD fellow in neurobiology, I specialize in circulating biomarkers to enhance Alzheimer’s and related dementia (ADRD) diagnosis in low-resource settings. My research also investigates how unique epidemiological burdens and comorbidities shape biomarker profiles in diverse populations, aiming to bridge the gap between cutting-edge science and real-world impact.